Cantor Fitzgerald Maintains Neutral on Alnylam Pharmaceuticals, Lowers Price Target to $205

Benzinga · 3d ago
Cantor Fitzgerald analyst Olivia Brayer Saunders maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Neutral and lowers the price target from $290 to $205.